{
    "clinical_study": {
        "@rank": "95578", 
        "arm_group": [
            {
                "arm_group_label": "OPC-12759 ophthalmic solution", 
                "arm_group_type": "Experimental", 
                "description": "OPC-12759 ophthalmic solution"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "OPC-12759 ophthalmic solution 0%"
            }, 
            {
                "arm_group_label": "OPC-12759 ophthalmic suspension", 
                "arm_group_type": "Active Comparator", 
                "description": "OPC-12759 ophthalmic suspension"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to verify whether OPC-12759 ophthalmic solution is effective\n      compared with placebo in dry eye patients. OPC-12759 ophthalmic suspension will be used as a\n      reference drug."
        }, 
        "brief_title": "Confirmatory Study of OPC-12759 Ophthalmic Solution", 
        "completion_date": {
            "#text": "May 2013", 
            "@type": "Actual"
        }, 
        "condition": "Dry Eye", 
        "condition_browse": {
            "mesh_term": [
                "Keratoconjunctivitis Sicca", 
                "Dry Eye Syndromes"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Out patient\n\n          2. Subjective complaint of dry eye that has been present for minimum 20 months\n\n          3. Ocular discomfort severity is moderate to severe\n\n          4. Corneal - conjunctival damage is moderate to severe\n\n          5. Unanesthetized Schirmer's test score of 5mm/5minutes or less\n\n          6. Best corrected visual acuity of 0.2 or better in both eyes\n\n        Exclusion Criteria:\n\n          1. Presence of anterior segment disease or disorder other than that associated with dry\n             eye\n\n          2. Ocular hypertension patient or glaucoma patient with ophthalmic solution\n\n          3. Anticipated use of any topically-instilled ocular medications or patients who cannot\n             discontinue the use during the study\n\n          4. Anticipated use of contact lens during the study\n\n          5. Patient with punctal plug\n\n          6. Any history of ocular surgery within 12 months\n\n          7. Female patients who are pregnant,possibly pregnant or breast feeding\n\n          8. Known hypersensitivity to any component of the study drug or procedural medications\n\n          9. Receipt of any investigational product within 4 months."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "209", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "August 6, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01660256", 
            "org_study_id": "037E-11-003", 
            "secondary_id": "JapicCTI-121920"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "OPC-12759 ophthalmic solution", 
                    "OPC-12759 ophthalmic suspension"
                ], 
                "description": "Instillation, 4 times/day for 4 weeks", 
                "intervention_name": "OPC-12759", 
                "intervention_type": "Drug", 
                "other_name": "rebamipide"
            }, 
            {
                "arm_group_label": "Placebo", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Rebamipide"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "June 9, 2013", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Kansai Region", 
                        "country": "Japan"
                    }, 
                    "name": "Kansai Region"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Kanto region", 
                        "country": "Japan"
                    }, 
                    "name": "Kanto region"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Kyushu region", 
                        "country": "Japan"
                    }, 
                    "name": "Kyushu region"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Tokai region", 
                        "country": "Japan"
                    }, 
                    "name": "Tokai region"
                }
            }
        ], 
        "location_countries": {
            "country": "Japan"
        }, 
        "number_of_arms": "3", 
        "official_title": "Confirmatory Study of OPC-12759 Ophthalmic Solution in Patients With Dry Eye", 
        "overall_official": {
            "affiliation": "Director of Division Dermatilogicals and Ophtalmolgicals, Otsuka Pharmaceutical Co., Ltd.", 
            "last_name": "Eiji Murakami", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Japan: Ministry of Health, Labor and Welfare", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "March 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "Change in fluorescein corneal staining scores", 
            "measure": "Efficacy:Change in fluorescein", 
            "safety_issue": "No", 
            "time_frame": "Week 2, 4"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01660256"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Otsuka Pharmaceutical Co., Ltd.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Otsuka Pharmaceutical Co., Ltd.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "August 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "June 2013"
    }
}